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Abstract
Background:  Low molecular weight heparin (LMWH) is in vast usage for treatment of
thromboembolic diseases such as deep venous thrombosis and acute coronary syndromes. There
are certain clinical situations where a quick point of care testing of the effect of LMWH would be
useful. At this point there are no point of care devices available in the market for monitoring the
effect of LMWH. Thrombelastography (TEG) evaluates the viscoelastic properties of blood during
coagulation. The clinical application of TEG in monitoring LMWH treatment is not yet well defined.
The purpose of this in vivo study was to systematically evaluate the most suitable TEG parameters
for evaluation of the antithrombotic effect of LMWH. We furthermore evaluated for the first time
the usefulness of the composite TEG parameter the Thrombodynamic Ratio (TDR) in monitoring
LMWH treatment.
Methods:  Healthy male volunteers (n = 7) were injected subcutaneously with the LMWH
dalteparin 120 IU/kg. TEG parameters and antifactor Xa levels were measures at baseline, 2, 4, 5
and 24 hours after the injection. Correlation between TEG parameters and antiXa were calculated.
The sensitivity and specificity of the TEG parameters for plasma levels of antiXa in the therapeutic
range of 0.5 - 1.0 U/ml were calculated.
Results: All basic TEG parameters correlated significantly with antiXa levels. Among the basic
parameters, the TEG reaction time R had the best correlation with antiXa levels with the most
favorable combination of sensitivity and specificity for the therapeutic range of antiXa levels (r =
0.82, p < 0.0001, sensitivity 68%, specificity 100%). The composite TEG parameter TDR
demonstrated the best correlation with antiXa levels, and an even more favorable combination of
sensitivity and specificity compared to any of the basic parameters (r = - 0.87, p < 0.0001, sensitivity
95%, specificity 79%).
Conclusion: The TEG reaction time R and TDR are the most suitable TEG parameters for
evaluation of the antithrombotic effect of dalteparin with a highly significant correlation with antiXa
levels in healthy male volunteers. Measures for uniform clinical use of these parameters are
proposed. Larger clinical trials are needed to correlate R and TDR with clinical outcomes.
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Introduction
Application of low molecular weight heparin (LMWH) in
the treatment of acute coronary syndromes and deep
venous thrombosis has been evaluated in several large-
scale trials [1-5]. The main advantage of the LMWH as
compared to the unfractionated heparin (UFH) is that the
LMWH can be administered in weight adjusted subcuta-
neous doses without the need for monitoring coagulation
parameters. There are, however, a number of circum-
stances where monitoring the effect of LMWH on the
coagulation system is desirable. These conditions include
bleeding situations, patients with renal failure, children
and patients with high or low body weight. In addition
preterm pregnant women with thrombophilia who are on
LMWH treatment constitute a risk of bleeding complica-
tions during regional anesthesia or surgical delivery [6,7].
The conventional test for monitoring the LMWH function
is anti-factor Xa activity level (antiXa) in plasma. The
antiXa measurement is however both time and labor
intensive and therefore not suited routine clinical applica-
tion. A point of care test reflecting the antithrombotic
effect of LMWH will therefore fulfill an important clinical
function [6]. At this point there are no point of care
devices available in the market for monitoring the effect of
LMWH.
Thrombelastography (TEG) is a point-of-care test for eval-
uation of hemostasis. It measures the viscoelastic proper-
ties of clotting blood. During the ex vivo clotting process,
changes in viscoelastic properties are dependent on the
amount and interaction of platelets and fibrinogen, as
well as the fibrin formation rate by thrombin [8]. Earlier
studies have shown correlation between TEG variables
and routine coagulation tests (platelet count, pro-
thrombin time, activated partial thromboplastin time,
antithrombin and fibrinogen) [9,10]. There is extensive
experience with TEG in monitoring hemostasis on
patients undergoing orthotopic liver transplantation and
open heart surgery where it is proven to be superior to
routine coagulation tests in predicting peri- and postoper-
ative bleeding and use of blood products [11,12]. Moni-
toring unfractionated heparin therapy by TEG has also
been described [13]. There are however only a few in vivo
studies available on monitoring LMWH therapy by TEG in
humans [14-17]. The clinical application of TEG in mon-
itoring LMWH treatment is not yet well defined. While
LMWH seems to alter all TEG parameters, the TEG reac-
tion time has been the parameter most investigated.
Whether the reaction time is the most suited parameter for
monitoring LMWH treatment has not been systematically
and adequately evaluated. Furthermore, there has so far
been no attempt on evaluation of a single integrated TEG
parameter consisting of several basic parameters for
assessment of LMWH treatment. We have previously
introduced the Thrombodynamic Ratio (TDR), a compos-
ite TEG parameter [18]. The purpose of this in vivo study
was to systematically examine the correlation between the
AntiXa and the basic TEG parameters. We furthermore
sought for the first time to evaluate the usefulness of TDR
in monitoring LMWH treatment. In addition measures for
uniform clinical use of TEG parameters are proposed.
Materials and methods
This study was approved by the Regional Review Board of
Copenhagen County, Denmark. Informed consent was
obtained before inclusion.
Thromboelastography
The principles of the thromboelastographic measurement
have previously been described [8,9]. The basic TEG
parameters include reaction time R, angle of alpha (α)
and Maximum Amplitude (MA). Reaction time is pro-
longed by clotting factor deficiencies, warfarin, unfrac-
tionated heparin and LMWH treatment [13,19]. Aspirin
has no effect on reaction time [20]. In the TEG literature,
the alteration of R value from baseline after the LMWH
injection is defined as ΔR. Thrombodynamic Ratio
(TDR)(18) is a composite TEG parameter defined as:
TDR has no units. As previously described the throm-
bophilic conditions have a tendency to increase MA and
α, and decrease R [21]. In contrast antithrombotic treat-
ment such as thrombolytics, and thrombin inhibitors
tend to decrease MA and α, and increase R. The TDR in
essence portrays an amplified profile of the prothrom-
botic or antithrombotic state in the sample. As a conse-
quence a large TDR value indicates a prothrombotic
condition and a small TDR indicates an antithrombotic
condition in the sample. We used a Thrombelastograph®
coagulation analyzer 5000C (Haemoscope Corp, Niles,
IL, USA). Celite activated TEG analysis was performed on
330 μl citrated whole blood that was recalcified with 30 μl
0.2 M CaCl2. The parameters R, α and MA were measured
and the average of the duplicate levels was recorded for
the statistical analysis. The TDR was calculated based on
the average of the duplicate levels of the basic parameters
and applied in the statistical analysis. All TEG analyzes
were performed within one hour after sample collection.
Blood sampling
Healthy male volunteers were treated with a single subcu-
taneous injection of dalteparin. No other antithrombotic
agents, including aspirin or non-steroidal anti-inflamma-
tory agents, were allowed a week prior to inclusion in the
study. The blood samples were collected just before the
injection of dalteparin as baseline values. After the subcu-
taneous injection of dalteparin sodium 120 IU/kg, (Frag-
min®, Pfizer, New York USA), blood samples were
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collected at 2, 4, 5 and 24 hours. Samples were analyzed
for antiXa level and the TEG parameters.
Anti-factor Xa analysis
For AntiXa analysis citrated blood was centrifuged at 2000
g for 10 minutes. All plasma samples were stored at -80°C
and then analyzed in batch. AntiXa was measured with
Chromogenic assay on STA-R®  apparatus (Diagnostica
Stago, France). The coefficient of variation was 2%.
Statistical Analysis
All data are presented as mean and standard deviation
(SD) unless otherwise indicated. Spearman correlation
coefficient (r) was calculated for correlation between the
TEG parameters and antiXa. P values less than 0.05 (two
tailed) were considered statistically significant. The sensi-
tivity and specificity of each TEG parameter for plasma
levels of antiXa in the therapeutic range of 0.5 - 1.0 U/ml
were calculated. The sensitivity was defined as number of
the true positives divided by the sum of true positives and
false negatives. The specificity was defined as number of
the true negatives divided by the sum of true negatives and
false positives. The cut off point was chosen as the mean
value of each parameter obtained from a sample of 49
healthy donors. These values were compatible with the
reference range provided by the manufacturer. Statistical
analyses were performed using Prism software version 5.0
(GraphPad Software Inc. La Jolla CA, USA) and MedCalc
version 10.3 (MedCalc Software, Mariakerke Belgium).
Results
Seven healthy volunteers (median age 36, total range 28-
56) were included. A significant correlation was observed
between antifactor Xa and all 3 basic TEG parameters
based on 21 pairs of data (Table 1). The levels at baseline
and 24 hours where the antiXa levels were zero were
excluded from the correlation analysis. A highly signifi-
cant correlation between TDR and AntiXa was observed (r
= - 0.87, p < 0.0001) (Figure 1). The sensitivity and specif-
icity of each TEG parameter and TDR for plasma levels of
antiXa in the therapeutic range was calculated using the
cut off point of 13 mm for R, 66° for alpha, 58 mm for MA
and 10 for TDR (Figure 1). The R values above 13 mm had
the highest specificity for therapeutic range of antiXa lev-
els. The MA values less than 58 mm and alpha less then
66° had the highest sensitivity for therapeutic range of
antiXa levels with poor specificity. TDR levels less than 10
had the highest combination of the sensitivity and specif-
icity for therapeutic range of antiXa levels. Plotting the
individual values over 24 hours for each subject after
dalteparin injection showed homogenous response meas-
ured by antiXa level, R and TDR (Figure 2).
Discussion
In this study we have demonstrated a strong correlation
between all basic TEG parameters and antiXa levels in
healthy volunteers receiving a single dose subcutaneous
injection of dalteparin. We furthermore demonstrated
that the Reaction time R had the overall most favorable
combination of correlation coefficient, sensitivity and
specificity for clinical use among the basic TEG parame-
ters. This finding demonstrated that R is the most suitable
basic parameter for monitoring LMWH treatment. In the
present study we demonstrated for the first time that the
composite TEG parameter TDR has a highly significant
correlation with AntiXa levels. It in fact has an even more
favorable combination of sensitivity and specificity for the
therapeutic range of antiXa levels than any of the basic
TEG parameters. The application of a composite TEG
parameter for monitoring unfractionated heparin has
been attempted in the past [13]. The composite parameter
used was termed Thrombodynamic Potential Index (TPI)
defined as: MA ￿ 100 (100 - MA)/2 ￿ K. The other known
composite TEG parameter is Clotting Index (CI) defined
as: CI = -0.6516R - 0.3772K + 0.1224MA + 0.0759α -
7.7922. The limitation of both of the above mentioned
factors is the parameter K. The Clotting time K was among
the original TEG parameters developed by Hartert and is
defined as distance or time from the 1 mm wide point on
TEG profile to the 20 mm wide point [8]. In the modern
antithrombotic treatment that includes single agents or
combination of agents such as, tissue plasminogen activa-
tors, glycoprotein IIb/IIIa inhibitors, thienopyridines,
thrombin inhibitors and selective factor X inhibitors it is
possible that due to antithrombotic action in vivo, the
TEG profile would never reach the wide point of 20 mm
making the above mentioned formulas useless. With this
in mind the TDR was developed, so that it is independent
of the parameter K. The clotting dynamics that K repre-
sents are also reflected in the angle of α. Since not only R
Table 1: Correlation coefficients of TEG parameters compared to anti-factor Xa. 
Correlation Coefficient (r) Sensitivity (%) Specificity (%) P value
R 0.82 68 100 <0.0001
α - 0.72 100 57 <0.0001
MA - 0.68 100 36 <0.0001
TDR - 0.87 95 79 <0.0001
Sensitivity and specificity of the TEG parameters for anti-factor Xa level in therapeutic range of 0.5 - 1.0 U/ml.
α: angle of Alpha, MA: maximum amplitude; R: reaction time, TDR: thrombodynamic ratio.Thrombosis Journal 2009, 7:14 http://www.thrombosisjournal.com/content/7/1/14
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but all the basic parameters were altered significantly by
dalteparin, it seemed intuitive that a composite parameter
such as TDR would correlate strongly with antiXa levels.
To our knowledge this is the first report of the application
of a composite TEG parameter for assessment of LMWH
treatment. The advantage of the composite TEG parameter
TDR is that it incorporates all the basic TEG parameters
provides a more user friendly approach to the concept of
TEG from a clinical standpoint. It is easier for the clinician
to consider a single parameter rather than 3 or 4 parame-
ters. The disadvantage of such composite parameter is that
it may diminish subtle changes measured in only one of
the parameters. In addition as seen in figure 2, due to the
mathematical composition of TDR, the coefficient of var-
iation is larger as compared to the basic TEG parameters.
There has been only one previously published in vivo
study on the application of TEG in monitoring dalteparin
therapy in humans. Shinoda and coworkers studied 28
patients with kidney failure who were monitored during
hemodialysis after receiving dalteparin [14]. The study
showed a weak correlation between reaction time and
antiXa (r = 0.402, p < 0.05). The timing of the sample col-
lection from the dalteparin injection was not specified
and the other TEG parameters were not analyzed. The
samples were obtained from the dialyzer during extracor-
poreal blood circulation that may have had an impact on
Correlation between Thrombodynamic Ratio (TDR) and AntiXa levels is demonstrated Figure 1
Correlation between Thrombodynamic Ratio (TDR) and AntiXa levels is demonstrated. The sensitivity and spe-
cificity of TDR for plasma levels of antiXa in the therapeutic range of 0.5 - 1.0 U/ml (horizontal dotted line) were calculated 
using cut off point of 10 (vertical dotted line). The dots in the left upper quadrant (A) represent TDR values less than 10 that 
correspond to therapeutic range of AntiXa. Dots in the right upper quadrant (B) are TDR values more than 10 that corre-
spond to therapeutic range of AntiXa. Dots in the left lower quadrant (C) are TDR values less than 10 that correspond to non 
therapeutic AntiXa and dots in the right lower quadrant (D) represent TDR values more than 10 that correspond to non ther-
apeutic AntiXa. The sensitivity was defined as number dots in A/A+C = 20/20+1 ≈ 0.95. The specificity was defined as number 
of dots in D/D+B = 11/11+3 ≈ 0.79.
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Anti-factor Xa (top), Thrombodynamic Ratio (middle) and Reaction time (bottom) levels plotted parallel at 2, 4, 5 and 24 hours  after injection of single subcutaneous injection of 120 IU/kg of dalteparin in seven healthy male volunteers Figure 2
Anti-factor Xa (top), Thrombodynamic Ratio (middle) and Reaction time (bottom) levels plotted parallel at 2, 
4, 5 and 24 hours after injection of single subcutaneous injection of 120 IU/kg of dalteparin in seven healthy 
male volunteers. Circles represent individual subjects.
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the results. Besides the case reports and the study by Shin-
oda, we indentified only 3 other in vivo studies in the lit-
erature regarding the application of TEG for monitoring
LMWH treatment in humans. Out of the 3 studies, the
only study with appropriate dosage and timing of the
sample collection that provided calculation of correlation
coefficient was by Carroll and co-workers, who examined
15 pregnant subjects with thrombophilia after treatment
with subcutaneous enoxaparin [17]. The parameter
applied in the latter study was ΔR with a correlation coef-
ficient of 0.90 comparable to the correlation found in the
present study and confirming the suitability of the TEG
parameters such as R or ΔR for such purpose. The other
TEG parameters were not specified. One of the limitations
of solely applying ΔR for monitoring LMWH treatment is,
that if the clinical situation does not allow a baseline
measurement of R then ΔR cannot be calculated and the
clinician is then left with a patient already injected with
LMWH and is interested in knowing the degree of antico-
agulation for bleeding risk assessment prior to a proce-
dure. For this reason, we propose that an absolute R value
above 13 mm is highly specific and absolute TDR value
less than 10 is highly sensitive for therapeutic range of
AntiXa levels.
Limitations
This study was limited due to small sample size. Further-
more this in vivo study was on healthy male volunteers
treated with dalteparin monotherapy. Since the dose of
dalteparin applied in this study was according to estab-
lished guidelines by the manufacturer, none of the sub-
jects reached supra-therapeutic levels of antiXa. In
addition none of the subjects had sub-therapeutic levels
of antiXa in the time intervals chosen in this study. The
correlation of TEG parameters with antiXa levels above 1
U/ml and below 0.5 U/ml were therefore not evaluated
and may need further investigation. These findings need
to be verified with the other LMWH's and co-medication
with other antithrombotic agents in patients of both gen-
der with various disease states, before a more general
usage of the method can be recommended.
Conclusion
Based on our observations, the TEG reaction time R and
the composite parameter of TDR have a substantial corre-
lation with anti-factor Xa levels in healthy volunteers. In
order to investigate the value and usefulness of TEG in
predicting the bleeding or thrombotic complications,
larger trials on patients treated with different antithrom-
botic agents including different LMWH preparations are
needed to correlate abnormal R and TDR values with neg-
ative clinical outcomes. The current study may be an
important first step.
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